Smith & Nephew SNATS

Smith & Nephew SNATS OCF Margin

The Operating Cash Flow Margin of Smith & Nephew SNATS (SNN) as of Nov 3, 2026 is 20.85 %. In the previous year, Operating Cash Flow Margin was 16.99 % — a change of 22.72% (higher).

OCF Margin

20.85 %

YoY

22.72%

Last updated:

Operating Cash Flow Margin of Smith & Nephew SNATS is 2025 20.85 % . Operating Cash Flow Margin of Smith & Nephew SNATS was 2024 16.99 % . It decreases by 22.72% higher compared to the previous year.

The Smith & Nephew SNATS OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
18.98 USD
Jan 1, 2019
22.73 USD
Jan 1, 2020
20.50 USD
Jan 1, 2021
16.83 USD
Jan 1, 2022
8.97 USD
Jan 1, 2023
10.96 USD
Jan 1, 2024
16.99 USD
Jan 1, 2025
20.85 USD
The Smith & Nephew SNATS OCF Margin history
YEAROCF MarginYoY
20.85 %+22.72%
16.99 %+55.04%
10.96 %+22.09%
8.97 %-46.67%
16.83 %-17.94%
20.50 %-9.80%
22.73 %+19.74%
18.98 %-17.01%
22.88 %+25.80%
18.18 %-18.19%
22.23 %+50.25%
14.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS Stock analysis

What does Smith & Nephew SNATS do? Smith & Nephew SNATS Inc operates in the medical device sector, focusing on orthopaedic implants and surgical solutions. The company generates revenue through knee and hip implant products used in joint replacement procedures, including revision surgeries. Its trauma and extremities segment offers internal and external devices for fracture stabilization and deformity correction. Sports Medicine & ENT segment sells joint repair products, arthroscopic equipment, and tissue resection devices for minimally invasive surgeries. Advanced Wound Management provides specialized wound care solutions, though specific products are not detailed in the description. The primary buyers are healthcare providers and hospitals globally, particularly in the United Kingdom, United States, and international markets. Orthopaedics and Sports Medicine & ENT segments target surgeons and orthopaedic specialists, while Advanced Wound Management serves wound care professionals. The company’s products are sold under its own brand, with no external brand names mentioned in the description. Revenue streams include direct sales of medical devices to hospitals and clinics, with no mention of subscription models or service-based fees. The company’s focus on surgical solutions and implants drives its market position, with key segments defined by product categories rather than geographic regions. No additional revenue streams like data services or digital platforms are referenced in the business description. Smith & Nephew SNATS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Smith & Nephew SNATS stock

Operating Cash Flow Margin of Smith & Nephew SNATS is 20.85 % in 2025.

Operating Cash Flow Margin of Smith & Nephew SNATS changed from 16.99 % to 20.85 %, representing a 22.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Smith & Nephew SNATS since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Smith & Nephew SNATS with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Smith & Nephew SNATS

All Key Metrics — Smith & Nephew SNATS